Human leukocyte antigen-restricted Epstein-Barr virus latent membrane protein 2-derived peptide-major histocompatibility complex (HLA-restricted EBV LMP2 pMHC)

HLA-restricted EBV LMP2-derived peptide–MHC complexes are specialized antigenic structures presented on the surface of cells infected with the Epstein-Barr virus (EBV), particularly those in a latent state (NIH, 2018) [1]. These complexes consist of short peptides derived from the EBV Latent Membrane Protein 2 (LMP2) bound to specific Human Leukocyte Antigen (HLA) class I molecules, such as HLA-A*02:01 or HLA-A*11:01 (JPT, 2024) [2]. In EBV-associated malignancies like nasopharyngeal carcinoma and Hodgkin lymphoma, these pMHC complexes serve as critical targets for the immune system, as they allow cytotoxic T lymphocytes (CTLs) to recognize and eliminate tumor cells (ASH, 2019) [3]. Therapeutic strategies targeting these complexes include TCR-engineered T-cell (TCR-T) therapies, TCR-like monoclonal antibodies, and bispecific T-cell engagers (BiTEs), which bypass the virus's natural immune evasion mechanisms (Frontiers, 2021) [4]. Clinical development focuses on optimizing the affinity and specificity of these agents to ensure potent anti-tumor activity while minimizing off-target cross-reactivity with similar self-peptides (NIH, 2024) [5]. Monitoring HLA status and LMP2 expression is essential for patient selection and assessing the risk of immune escape through HLA downregulation (MDPI, 2019) [6].

Other names

EBV LMP2 pMHCHLA-A*02:01/LMP2 complexHLA-A*11:01/LMP2 complexLMP2-derived peptide-MHC complexEBV LMP2-derived peptide-HLA complexLMP2A-HLA complex

Targeted by engineered T-cell receptors (TCRs) or TCR-like antibodies to induce cytotoxic T-lymphocyte (CTL) mediated killing of EBV-infected tumor cells.